
Disha Malani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2209854/publications.pdf Version: 2024-02-01



ΠΙSHA ΜΑΙ ΑΝΙ

#	Article	IF	CITATIONS
1	Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Scientific Reports, 2014, 4, 5193.	3.3	243
2	Immunogenomic Landscape of Hematological Malignancies. Cancer Cell, 2020, 38, 380-399.e13.	16.8	109
3	Aggressive natural killer-cell leukemiaÂmutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nature Communications, 2018, 9, 1567.	12.8	107
4	Drug response prediction by inferring pathway-response associations with kernelized Bayesian matrix factorization. Bioinformatics, 2016, 32, i455-i463.	4.1	87
5	Consistency in drug response profiling. Nature, 2016, 540, E5-E6.	27.8	76
6	Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. Cancer Discovery, 2022, 12, 388-401.	9.4	73
7	HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. Leukemia, 2017, 31, 301-309.	7.2	61
8	Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML. Leukemia, 2017, 31, 1187-1195.	7.2	44
9	Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML. Leukemia, 2019, 33, 2548-2553.	7.2	25
10	Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies. Cancer Research, 2019, 79, 2466-2479.	0.9	23
11	Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling. Oncotarget, 2016, 7, 37407-37419.	1.8	16
12	Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. Npj Precision Oncology, 2021, 5, 71.	5.4	12
13	KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia. Leukemia, 2020, 34, 2780-2784.	7.2	6
14	FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML. Scientific Reports, 2021, 11, 23565.	3.3	6
15	High-Content Imaging to Phenotype Human Primary and iPSC-Derived Cells. Methods in Molecular Biology, 2021, 2185, 423-445.	0.9	4
16	High-Throughput Functional Ex-Vivo Drug Testing and Multi-Omics Profiling in Patients with Acute Myeloid Leukemia. Blood, 2019, 134, 4641-4641.	1.4	1
17	Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles. Blood, 2017, 130, 854-854.	1.4	1
18	High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML. Blood, 2012, 120, 288-288.	1.4	1

DISHA MALANI

#	Article	IF	CITATIONS
19	AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex Vivo Patient Cells with in Vitro Cell Lines. Blood, 2014, 124, 2163-2163.	1.4	1
20	Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib. Blood, 2011, 118, 2487-2487.	1.4	0
21	High-Throughput Drug Sensitivity and Resistance Testing (DSRT) Platform Reveals Novel Candidate Drugs For Advanced Phase BCR-ABL1-Positive Leukemia. Blood, 2013, 122, 2719-2719.	1.4	Ο
22	Exome Sequencing of Aggressive Natural Killer Cell Leukemia and Drug Profiling Highlight Candidate Driver Pathways in Malignant Natural Killer Cells. Blood, 2015, 126, 700-700.	1.4	0
23	Mutational Landscape of Aggressive Natural Killer Cell Leukemia and Drug Sensitivity Profiling Reveal Therapeutic Options in Natural Killer Cell Malignancies. Blood, 2016, 128, 2921-2921.	1.4	0